## Clinical Diagnosis This patient has developed **acute, significant anticholinergic adverse effects** (urinary retention, constipation, tachycardia) from benztropine therapy. The absence of infection and preserved mental status rule out UTI or delirium. The constellation of symptoms represents a clinically significant anticholinergic toxidrome requiring **immediate discontinuation** of the offending agent. **Key Point:** When anticholinergic side effects are acute and involve multiple organ systems (urinary, GI, cardiovascular), the most appropriate immediate next step is **discontinuation** of the anticholinergic drug — not dose reduction. ## Anticholinergic Adverse Effects in Parkinson's Disease | System | Adverse Effect | Mechanism | |--------|---|---| | **Urinary** | Urinary retention, hesitancy | Decreased detrusor muscle tone; increased sphincter tone | | **GI** | Constipation, dry mouth | Decreased GI motility; reduced salivary secretion | | **Cardiovascular** | Tachycardia, palpitations | Loss of vagal tone | | **Ocular** | Mydriasis, cycloplegia | Ciliary and iris paralysis | | **CNS** | Memory impairment, confusion (especially elderly) | Reduced cholinergic activity in cortex | **High-Yield:** Anticholinergic drugs (benztropine, trihexyphenidyl) are most effective for **tremor and rigidity** in Parkinson's disease but carry a narrow therapeutic window, especially in patients >50 years. When acute urinary retention occurs, the drug must be stopped immediately. ## Why Discontinue Benztropine (Option A)? **Clinical Pearl:** Acute urinary retention is a **medical emergency** requiring immediate removal of the causative agent. Continuing or merely reducing the dose of benztropine risks worsening retention, bladder injury, or hydronephrosis. 1. **Discontinue benztropine immediately** - Acute urinary retention + constipation + tachycardia = multi-system anticholinergic toxicity - Dose reduction (Option B) is insufficient when retention is already established; the drug must be stopped - KD Tripathi explicitly states: anticholinergic drugs are **contraindicated** in patients with urinary retention or prostatic hypertrophy 2. **Switch to a dopamine agonist** (e.g., pramipexole, ropinirole) - Dopamine agonists provide effective tremor and rigidity control without anticholinergic burden - Preferred alternative in patients who develop intolerable anticholinergic side effects - Per Harrison's Principles: dopamine agonists are the preferred agents when anticholinergics must be withdrawn ## Why Not Option B (Dose Reduction + Bethanechol)? - Dose reduction is appropriate for **mild, tolerable** side effects (e.g., dry mouth, mild constipation) - **Acute urinary retention** is not a mild side effect — it requires immediate cessation of the offending drug - Adding bethanechol to counteract an ongoing anticholinergic drug is pharmacologically illogical in the acute setting; the correct approach is to remove the cause - Bethanechol use alongside a continued anticholinergic creates competing pharmacological effects and does not address the root cause ## Why Not Options C or D? - **Option C:** Continuing benztropine at the same dose while managing symptoms symptomatically is inappropriate — it perpetuates the cause of the problem - **Option D:** Urodynamic studies are not indicated acutely; the etiology (drug-induced) is clear and must be addressed first ## Supportive Measures After Discontinuation - **Urinary retention:** Catheterization if voiding does not resume spontaneously after drug withdrawal - **Constipation:** Increase fluid intake, dietary fiber, osmotic laxatives (polyethylene glycol) - **Tachycardia:** Usually resolves within 24–48 hours of discontinuation; monitor HR and BP [cite: KD Tripathi 8e Ch 8 — Anticholinergic Drugs; Harrison 21e Ch 429 — Parkinson's Disease]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.